# Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)

> **NCT06663176** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Thirty Respiratory Limited** · enrollment: 60 (estimated)

## Conditions studied

- Non-Cystic Fibrosis Bronchiectasis

## Interventions

- **DRUG:** RESP302
- **DRUG:** RESP303

## Key facts

- **NCT ID:** NCT06663176
- **Lead sponsor:** Thirty Respiratory Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-16
- **Primary completion:** 2028-02-05
- **Final completion:** 2028-05-05
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06663176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06663176, "Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06663176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*